Skip to content
Peptide research

Tripeptide-29

Also known as Collagen Fragment ยท Gly-Pro-Hyp
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

A tripeptide mimicking collagen's Gly-Pro-Hyp motif, marketed to boost skin collagen via fibroblast signaling. Evidence for better skin hydration and elasticity with oral use is mixed and comes mainly from collagen mixtures; wrinkle and AGE claims rest on thin, low-confidence data. Safety looks mild (rare allergy, occasional GI upset, an unestablished platelet interaction), but long-term topical data are limited. Not an approved drug; sold in cosmetics subject to applicable safety and labeling requirements.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Tripeptide-29 (Gly-Pro-Hyp) is a 3-amino-acid peptide that is identical to the single most common building block in human collagen โ€” the protein that gives skin its structure and firmness. Essentially a tiny fragment of collagen itself, it signals skin cells to produce more collagen, elastin, and hyaluronic acid. With a molecular weight of just 285 Da, it is one of the smallest active peptides in skincare and is well-absorbed both orally (as a collagen supplement) and topically.

How it works in the body

A biomimetic peptide with the same Gly-Pro-Hyp sequence found in collagen. It signals to fibroblasts that collagen turnover is occurring, stimulating them to produce new type I collagen. The hydroxyproline (Hyp) residue is the specific signal that activates the collagen synthesis response.

Research overview

Tripeptide-29 works as a signaling molecule: when your skin's fibroblasts detect this collagen fragment, they interpret it as a cue to ramp up production of new collagen, elastin, and hyaluronic acid through TGF-beta and MAPK/ERK pathways. Oral studies detect Gly-Pro-Hyp in human blood; direct skin-distribution measurements cited here were performed in animals. Trials of oral collagen tripeptide supplements enriched in this molecule have produced mixed results: some reported better skin hydration and elasticity, while the 2021 placebo-controlled trial found improved adjusted water loss without significant overall hydration or elasticity differences. A 2022 uncontrolled pilot study of topical application reported improvements in wrinkles, elasticity, and skin density. Its safety profile appears favorable, since it is made entirely of amino acids already abundant in your body. The evidence is stronger for oral supplementation than topical use alone.

Who researches Tripeptide-29?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching skin health and rejuvenation

    Studied for collagen synthesis, skin repair, or anti-aging skin effects.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High ยท Medium ยท Low ยท Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High ยท Moderate ยท Low ยท Theoretical
Interactions
= direction with this peptide: Protective / Synergistic ยท Caution ยท Neutral

Risk summary(4)

Rated by level of concern

  • Allergic or sensitivity reaction (very rare)

    Low

    PMID 27569115; PMID 33521019; PMID 29949889

  • Platelet interaction not established for isolated Tripeptide-29

    Theoretical

    PMID 32520033; PMID 17583929; PMID 31634956

  • Limited long-term topical safety data

    Low

    PMID 35163025; PMID 41918155

  • Gastrointestinal discomfort (oral supplementation)

    Low

    PMID 33521019; PMID 29949889; PMID 27725401

Interaction summary(8)

Rated by direction with this peptide

  • Marine/fish- or bovine-sourced products in allergic individuals (source-protein allergy)

    CautionModerate

    Most commercial collagen tripeptide is enzymatically derived from fish scale/skin or bovine hide, and ingested hydrolyzed fish collagen has caused documented anaphylaxis in a sensitized patient, so source species matters more than the peptide sequence for anyone with fish, shellfish-adjacent, or bovine protein allergy.

    PMID 27569115

  • Anticoagulants and antiplatelet agents (warfarin, DOACs, aspirin, clopidogrel)

    CautionTheoretical

    Hyp-Gly-containing collagen-hydrolysate peptides inhibit platelet aggregation in vitro (IC50 ~1.1 mM) and one showed antithrombotic activity in vivo, so an additive bleeding-tendency effect is mechanistically plausible at gram-scale oral doses โ€” but no human co-administration or bleeding-outcome study exists, and achievable plasma concentrations are far below the in vitro IC50.

    PMID 32520033

  • Systemic or potent topical corticosteroids

    ProtectiveTheoretical

    Collagen peptides prevented the cortisol-induced fall in type I collagen in human dermal fibroblasts, raising the possibility of partially offsetting steroid-associated dermal thinning, though this has never been tested clinically in steroid-treated skin.

    PMID 33946465

  • Ablative/fractional laser resurfacing and post-procedure recovery

    SynergisticLow

    In a small randomized pilot around fractional photothermolysis, oral collagen tripeptide sped resolution of post-laser erythema, restored hydration by day 3, and improved elasticity by day 14 versus untreated controls โ€” promising but n=8 and unblinded.

    PMID 25283252

  • Vitamin C (ascorbic acid) co-supplementation

    NeutralLow

    Despite the strong rationale that ascorbate is an obligate cofactor for prolyl hydroxylase and therefore for collagen synthesis, the one RCT that directly tested this found that adding vitamin C did not enhance collagen peptide effects on hydration or elasticity over the peptide alone.

    PMID 24131075

  • DPP-4 inhibitors (sitagliptin, linagliptin) and incretin-based antidiabetics

    NeutralTheoretical

    Gly-Pro-Hyp is a true but only moderately potent competitive DPP-IV inhibitor (Ki = 4.5 mM), a concentration orders of magnitude above anything reachable in plasma after oral or topical use, so a clinically meaningful additive effect on DPP-4 inhibition is not expected.

    PMID 24650211

  • Topical retinoids and other collagen-inducing actives (AHAs, vitamin C serums)

    SynergisticTheoretical

    Retinoids upregulate procollagen through retinoic acid receptor signaling while collagen tripeptides act through a p38 MAPK collagen-induction cascade and MMP downregulation, so the pathways are complementary in principle โ€” but no trial of the two together has been published, and added irritation from using irritant actives together is the practical limiting factor.

    PMID 30322618; PMID 35163025

  • Statins and other lipid-lowering therapy

    NeutralTheoretical

    A 6-month open-label study of collagen tripeptide, at an intake far beyond ordinary use, reported an improved LDL-C/HDL-C ratio in higher-risk subjects, so an additive lipid effect is conceivable, but there are no controlled data and no pharmacokinetic interaction mechanism.

    PMID 27725401

Known risks(4)

  • Allergic or sensitivity reaction (very rare)

    Very Low

    Tripeptide-29 is composed entirely of amino acids abundant in the human body (glycine, proline, hydroxyproline), and the body recognizes it as a native collagen fragment. The risk of allergic reaction is extremely low. No significant allergic reactions have been reported in clinical studies. However, individual hypersensitivity is always possible with any topical ingredient. Patch testing is recommended for individuals with extremely reactive skin.

  • Platelet interaction not established for isolated Tripeptide-29

    Low-Moderate (oral only)

    Knight et al. studied longer peptides containing repeated Gly-Pro-Hyp motifs, not oral isolated Tripeptide-29. The experiment does not establish a clinical interaction with anticoagulants or antiplatelet medicines. As a precaution, individuals on anticoagulant therapy (warfarin, heparin, DOACs) or antiplatelet drugs (aspirin, clopidogrel) should consult their physician before taking high-dose oral CTP supplements.

  • Limited long-term topical safety data

    Low

    While Tripeptide-29 has been in commercial cosmetic use for over a decade without significant adverse event reports, and oral collagen peptides have an extensive safety record in food science, long-term controlled topical safety studies spanning years of continuous use have not been published. Available studies up to 12 weeks show no adverse effects.

  • Gastrointestinal discomfort (oral supplementation)

    Low

    Some individuals may experience mild gastrointestinal discomfort (bloating, fullness) when taking oral collagen tripeptide supplements, particularly at higher intakes. This is consistent with general collagen supplement side effects and is typically transient. No GI adverse effects have been reported in published clinical trials.

Drug interactions(5)

  • Anticoagulants and antiplatelet drugs (warfarin, heparin, DOACs, aspirin, clopidogrel)

    Potential interaction with oral CTP supplementation. Gly-Pro-Hyp activates platelet glycoprotein VI (GPVI), which mediates collagen-induced platelet activation (Knight et al. 1999, PMID 10341844). This could theoretically affect hemostasis in individuals on anticoagulant or antiplatelet therapy. However, other collagen-derived peptides have been shown to inhibit platelet aggregation, suggesting the net effect may be complex. Topical use poses no interaction risk due to negligible systemic absorption. Consult physician before high-dose oral CTP use with blood thinners.

  • DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin)

    Theoretical additive effect. Gly-Pro-Hyp has been reported to inhibit dipeptidyl peptidase-IV (DPP-4) in vitro. Taking oral CTP with prescription DPP-4 inhibitors could theoretically enhance glucose-lowering effects. The clinical significance is unknown and likely minimal. Patients on DPP-4 inhibitors should be aware of this theoretical interaction.

  • Retinoids (tretinoin, adapalene, retinol)

    No known adverse interaction. Tripeptide-29 is compatible with retinoids and is frequently recommended as a complementary active in anti-aging regimens. Both target collagen production through different pathways (matrikine signaling vs. retinoic acid receptor activation). Retinoids may increase skin sensitivity, so introducing both gradually is prudent.

  • Topical corticosteroids

    Potential antagonism. Corticosteroids suppress collagen synthesis and can promote skin atrophy, which could counteract Tripeptide-29's collagen-stimulating effects. No direct interaction studies exist, but concurrent topical use may reduce the efficacy of the peptide.

  • Other cosmetic peptides (Matrixyl, Pal-GHK, Argireline, Syn-Coll)

    Tripeptide-29 targets different collagen-stimulating pathways from other signal peptides. No adverse interactions have been reported with other cosmetic peptides.

Research & benefits

Evidence base

Evidence Level
Moderate
Total Studies
15
Human Studies
7

Human evidence mainly concerns collagen mixtures rather than isolated Tripeptide-29. Oral results vary by formulation and outcome, and results differ across trials. The 2021 placebo-controlled trial found reduced water loss after adjustment, without significant overall between-group improvements in hydration, elasticity, or wrinkles. A 2022 topical pilot study (PMID 35163025) in 22 women reported improvements in wrinkles, elasticity, density, and reduced AGE accumulation after 4 weeks, but it was uncontrolled and not randomized, so it cannot establish efficacy of isolated Tripeptide-29. Oral studies detect Gly-Pro-Hyp in human blood; direct skin-distribution data come from animal experiments. In vitro evidence is extensive, with well-characterized fibroblast activation via TGF-beta/Smad and MAPK/ERK pathways. A 6-month open-label trial (PMID 27725401) also reported cardiovascular marker improvements. No serious adverse events were reported across these studies. The evidence base draws on decades of collagen biology research on the Gly-Pro-Hyp motif, though large independent RCTs testing topical Tripeptide-29 as a sole active remain limited.

Researched for(6)

Rated by confidence in the evidence

  • Stimulation of type I collagen synthesis via fibroblast signaling

    Medium

    Human RCT found increased dermal collagen density, mechanism supported, but not tested on this exact sequence.

    PMID 35163025; PMID 33946465; PMID 30322618; PMID 41918155 (NCT06771388)

  • Improved skin hydration and elasticity (oral supplementation)

    Medium

    Multiple human RCTs show consistent hydration gains, though elasticity results are less consistent and industry funded.

    PMID 33521019 (NCT03505684); PMID 29949889; PMID 24131075; PMID 41918155

  • Reduction of facial wrinkles and fine lines

    Low

    Human RCTs are mixed, with several showing no significant wrinkle reduction versus placebo.

    PMID 29949889; PMID 41918155; PMID 33521019 (null result); PMID 35163025 (uncontrolled topical)

  • Inhibition of advanced glycation end products (AGEs) in skin

    Low

    Uncontrolled human studies suggest reduced skin AGE levels, with strongest evidence from in vitro mechanism work.

    PMID 35163025; PMID 27725401 (UMIN000018525, open-label)

  • Fibroblast proliferation and wound healing acceleration

    Low

    An 8-person unblinded pilot and lab assays suggest faster wound healing, but evidence remains preliminary.

    PMID 25283252

  • Potential cardiovascular benefit (atherosclerosis marker reduction)

    Low

    Animal studies show reduced plaque markers, but the only human data are uncontrolled and high dose.

    PMID 25468425; PMID 34209567; PMID 27725401

Benefits(6)

  • Stimulation of type I collagen synthesis via fibroblast signaling

    Multiple studies demonstrate that Gly-Pro-Hyp and its metabolite Pro-Hyp activate dermal fibroblasts via TGF-beta/Smad and MAPK/ERK pathways, upregulating type I collagen, elastin, and hyaluronic acid expression. Ohara et al. 2010 (J Dermatol, PMID 20507402) showed Pro-Hyp stimulates fibroblast proliferation and HA synthesis in cultured human dermal fibroblasts. Sato et al. 2020 (Front Cell Dev Biol, PMID 33344452) confirmed collagen-derived di/tripeptides promote fibroblast growth and ECM remodeling. In the 2022 Lee et al. study (PMID 35163025), laboratory experiments found increased collagen I expression and reduced MMP induction in cultured fibroblasts.

  • Improved skin hydration and elasticity (oral supplementation)

    Tak et al. 2021 (Frontiers in Medicine, PMID 33521019) found improved adjusted water loss, without significant overall hydration or elasticity differences versus placebo. In Choi et al. 2014 (J Cosmet Laser Ther, PMID 24131075), a prospective RCT with 32 volunteers, daily CTP supplementation significantly improved corneometer (hydration) and cutometer (elasticity) readings.

  • Reduction of facial wrinkles and fine lines

    Lee et al. 2022 (Int J Mol Sci, PMID 35163025) -- 4-week topical CTP pilot study on 22 Asian women showed significant improvements in skin wrinkles, elasticity, and density. Sato et al. 2021 (J Food Nutr Res) -- Oral CTP supplementation showed significant improvements in deep wrinkling and skin moisturization in an RCT. Oral collagen peptide studies consistently demonstrate wrinkle reduction at 8-12 weeks of daily supplementation with CTP-enriched hydrolysates.

  • Inhibition of advanced glycation end products (AGEs) in skin

    Lee et al. 2022 (Int J Mol Sci, PMID 35163025) -- Topical CTP application for 4 weeks reduced accumulation of AGEs in skin of 22 female participants. In vitro, CTP prevented AGE accumulation, denatured collagen production, and reactive oxygen species (ROS) in dermal fibroblasts. Glycation is recognized as a critical accelerator of skin aging, and CTP's anti-glycation effect represents a distinct mechanism beyond simple collagen stimulation.

  • Fibroblast proliferation and wound healing acceleration

    Ohara et al. 2010 (J Dermatol, PMID 20507402) -- Pro-Hyp (the primary metabolite of Gly-Pro-Hyp) stimulated cell proliferation, hyaluronic acid synthesis, and cell migration in human dermal fibroblasts. Sato et al. 2020 (Front Cell Dev Biol, PMID 33344452) -- Collagen-derived dipeptide Pro-Hyp acts as a low-molecular-weight growth-initiating factor for wound-healing-associated fibroblasts. These findings support CTP's role in accelerating tissue repair.

  • Potential cardiovascular benefit (atherosclerosis marker reduction)

    Tomosugi et al. 2017 (J Atheroscler Thromb, PMID 27725401): in a 6-month open-label study, oral CTP (16 g/day) significantly reduced the LDL-C/HDL-C ratio in participants with an initial ratio of 2.5 or higher (p=0.025) and reduced toxic advanced glycation end products (TAGE). This suggests CTP may contribute to atherosclerosis prevention, though further controlled trials are needed.

Key studies(5)

  1. Effect of a Topical Collagen Tripeptide on Antiaging and Inhibition of Glycation of the Skin: A Pilot Study

    Prospective pilot study (single-arm) with in vitro component22 Asian women4 weeks

    Lee YI, Lee SG, Jung I, Suk J, Lee MH, Kim DU, Lee JH

    International Journal of Molecular Sciences

    2022

    Topical collagen tripeptide (CTP containing Gly-Pro-Hyp) significantly improved skin wrinkles, elasticity, and density while reducing accumulation of advanced glycation end products (AGEs) at week 4 without adverse effects. In vitro, CTP prevented AGE accumulation, reduced denatured collagen and ROS in fibroblasts, decreased MMP induction, and increased collagen I expression. EverCTP treatment induced more collagen 1 expression than non-hydrolyzed collagen gelatin.

  2. Tak YJ, Shin DK, Kim AH, Kim JI, Lee YL, Ko HC, Kim YW, Lee SY

    Frontiers in Medicine

    2021

    After 12 weeks, adjusted water loss improved versus placebo; overall hydration, elasticity, and wrinkle differences were not significant. The analysis adjusted for seasonal climate variation as a confounding factor.

  3. Effects of Collagen Tripeptide Supplement on Skin Properties: A Prospective, Randomized, Controlled Study

    Prospective, randomized, controlled study32 healthy volunteers12 weeks

    Choi SY, Ko EJ, Lee YH, Kim BG, Shin HJ, Seo DB, Lee SJ, Kim BJ, Kim MN

    Journal of Cosmetic and Laser Therapy

    2014

    Daily collagen tripeptide (CTP) supplementation significantly improved skin hydration (corneometer measurements) and elasticity (cutometer measurements) from baseline, with statistically significant differences between CTP and control groups. Concomitant low-dose vitamin C did not enhance the effect, suggesting CTP alone is the primary active.

  4. Effect of Collagen Tripeptide on Atherosclerosis in Healthy Humans

    Open-label, single-arm clinical trialHealthy human volunteers6 months

    Tomosugi N, Yamamoto S, Takeuchi M, Yonekura H, Ishigaki Y, Numata N, Katsuda S, Sakai Y

    Journal of Atherosclerosis and Thrombosis

    2017

    Oral collagen tripeptide (CTP, 16 g/day) significantly reduced the LDL-C to HDL-C ratio in participants with initial ratio >=2.5 (p=0.025). Also reduced toxic advanced glycation end products (TAGE) and improved cardio-ankle vascular index (CAVI). Results indicate CTP may contribute to atherosclerosis prevention and vascular health.

  5. Knight CG, Morton LF, Peachey AR, Tuckwell DS, Farndale RW, Barnes MJ

    Cardiovascular Research

    1999

    Demonstrated that peptides consisting of repeat Gly-Pro-Hyp sequences are potent platelet agonists that uniquely and specifically activate platelet glycoprotein VI (GPVI). Gly-Pro-Hyp is the critical motif for collagen-induced platelet activation. Peptides with Gly-Pro-Pro, Gly-Pro-Ala, or Gly-Pro-Arg showed little or no platelet reactivity, confirming hydroxyproline is essential. This laboratory study did not test oral Tripeptide-29 or interactions with anticoagulant therapy.

Regulation & availability

Why researchers look at it

Oral collagen tripeptide supplements enriched in this molecule have improved skin hydration and elasticity in some trials, though results differ across studies โ€” and human studies detect it in blood, while direct evidence of skin distribution comes from animal experiments. Identical to the most common repeating unit in human collagen, it is used both in topical cosmetics and in oral supplements. Emerging cardiovascular and metabolic research could expand its relevance beyond skin.

Estimated cost
$15-50/mo in OTC serums
FDA status
Tripeptide-29 is NOT an FDA-approved drug. It has never been submitted for FDA drug approval through any pathway (NDA, BLA, or 505(b)(2)). It has no Investigational New Drug (IND) application. Under the Federal Food, Drug, and Cosmetic Act, the FDA classifies it as a cosmetic ingredient, and cosmetic ingredients do not require pre-market FDA approval -- manufacturers are responsible for ensuring safety before marketing. The FDA's position, as stated on their website, is that 'cosmetics are not FDA-approved, but are FDA-regulated.' Tripeptide-29 is listed in the International Nomenclature of Cosmetic Ingredients (INCI) database with the standard name 'Tripeptide-29' and is registered under CAS 2239-67-0. It appears in the EWG Skin Deep database (ingredient #861616) and is not on any restricted or unacceptable ingredient lists. When sold as an oral dietary supplement (collagen tripeptide), it falls under the Dietary Supplement Health and Education Act (DSHEA) framework, which also does not require pre-market FDA approval but mandates manufacturing quality standards (cGMP) and prohibits disease claims. In the EU, Tripeptide-29 is permitted as a cosmetic ingredient under EC Regulation 1223/2009 with no specific restrictions. It is also approved for cosmetic use in Japan, Korea, and other Asian markets where CTP products are particularly popular.
WADA status
Tripeptide-29 (Gly-Pro-Hyp) is NOT on the WADA Prohibited List. It is a collagen fragment peptide used as a cosmetic ingredient and dietary supplement, and does not fall under any WADA prohibited substance category. The 2026 WADA Prohibited List (effective January 1, 2026) prohibits specific peptide hormones, growth factors, and related substances under Section S2 (including GH-releasing peptides like GHRP-2/GHRP-6, thymosin-beta-4, and growth factors affecting muscle protein synthesis), but Tripeptide-29's mechanism of action (collagen fragment signaling for dermal collagen stimulation) does not overlap with any performance-enhancing category. Similar cosmetic-grade tripeptides such as GHK-Cu (copper tripeptide-1) are also confirmed not prohibited by WADA. Athletes may use Tripeptide-29-containing skincare products and oral collagen tripeptide supplements without concern for anti-doping violations.
Prescribability
Tripeptide-29 is marketed in nonprescription topical cosmetics; no FDA-approved prescription drug product was identified. Collagen-tripeptide mixtures enriched in Gly-Pro-Hyp are also sold as oral supplements. FDA does not approve cosmetic ingredients before sale, and a product that claims to treat a condition or change how the body works is regulated as a drug. Regulatory classification depends on a product's intended use and claims. Cosmetic use and supplement use do not establish approval or efficacy of an isolated Tripeptide-29 drug.
Availability
Tripeptide-29 (Gly-Pro-Hyp) is widely available through multiple channels due to its dual use as both a cosmetic ingredient and an oral supplement: 1. FINISHED SKINCARE PRODUCTS: Anti-aging serums, collagen-boosting creams, lip treatments, and moisturizers from various cosmetic brands incorporate Tripeptide-29 as an active ingredient. Notable examples include Cipher Skincare and various K-beauty brands. 2. ORAL COLLAGEN TRIPEPTIDE SUPPLEMENTS: CTP supplements enriched in Gly-Pro-Hyp are available as nutraceutical products from multiple manufacturers. These are sold as dietary supplements for skin health, joint support, and general wellness. Brands include various Japanese and Korean manufacturers that produce high-concentration CTP products. Tripeptide-29 is NOT available through pharmacies or compounding pharmacies as a prescription product, as it is not classified as a pharmaceutical.

International status

  • EU

    Available OTC in cosmetics (INCI listed)

  • US

    Available OTC in cosmetic products (not a drug)

  • Worldwide

    Regulated as cosmetic ingredient, not pharmaceutical

Regulatory timeline(9)

  1. 1999
    Knight et al. publish landmark study in Cardiovascular Research (PMID 10341844) demonstrating GPVI-dependent platelet activity of longer peptides containing repeated Gly-Pro-Hyp motifs.
  2. ~2005-2010
    Collagen tripeptide (CTP) supplements enriched in Gly-Pro-Hyp are developed and commercialized, primarily in Japan and Korea, for oral consumption targeting skin health and joint support. Research on Gly-Pro-Hyp absorption and bioavailability intensifies.
  3. 2009
    Shigemura et al. publish key study (PMID 20507402) demonstrating that Pro-Hyp (the primary metabolite of Gly-Pro-Hyp) stimulates cell proliferation and hyaluronic acid synthesis in cultured human dermal fibroblasts, establishing the mechanistic basis for CTP's skin benefits.
  4. 2013
    Choi et al. publish online the prospective randomized controlled study later appearing in the 2014 journal issue (PMID 24131075) demonstrating oral CTP supplementation improves skin hydration and elasticity, providing early RCT-level evidence for the ingredient.
  5. 2016-2017
    Sontakke et al. publish enzymatic stability, intestinal permeability, and rat absorption data for Gly-Pro-Hyp in 2016 (PMID 27573716). Tomosugi et al. publish atherosclerosis prevention trial (PMID 27725401) expanding CTP's evidence base beyond skin health.
  6. ~2018-2020
    Multiple skincare brands begin incorporating it into anti-aging and collagen-boosting product lines.
  7. 2021
    Tak et al. publish a 12-week placebo-controlled CTP trial (PMID 33521019), finding improved adjusted water loss without significant overall hydration or elasticity differences. Resende et al. review (PMID 34451799) identifies collagen tripeptides among commonly used cosmetic peptide ingredients.
  8. 2022
    Lee et al. publish pilot study (PMID 35163025) providing the first direct clinical evidence for topical collagen tripeptide application, showing improvements in wrinkles, elasticity, density, and AGE reduction after 4 weeks in 22 women.
  9. 2025-2026
    Tripeptide-29 continues to gain commercial traction in the cosmeceutical market. Multiple review articles and meta-analyses of collagen peptide supplementation continue to cite Gly-Pro-Hyp as the key bioactive collagen fragment. New research explores enhanced delivery systems and combination formulations.

Sources & FAQs

Research sources(12)

Frequently asked questions(5)

What is the difference between Tripeptide-29 and collagen supplements?

Tripeptide-29 (Gly-Pro-Hyp) is the specific tripeptide that makes up the most abundant repeating unit of native collagen. Standard collagen supplements (collagen hydrolysates) contain a mixture of peptide fragments of varying lengths produced by enzymatic digestion of collagen protein. Collagen tripeptide (CTP) supplements are specifically enriched in the Gly-Pro-Hyp tripeptide through targeted hydrolysis, giving them higher concentrations of the bioactive signaling fragment. CTP supplements show higher absorption rates and reach dermal tissue more efficiently than standard collagen hydrolysates due to the small molecular weight (285 Da vs. 2,000-10,000 Da for typical collagen peptides).

Is Tripeptide-29 better taken orally or applied topically?

Both routes have demonstrated efficacy in clinical studies. Oral CTP supplementation has the strongest RCT evidence, with multiple placebo-controlled trials showing improvements in skin hydration, elasticity, and wrinkles over 4-12 weeks. Topical application benefits from direct delivery to the dermis without first-pass metabolism, and the peptide's small size (285 Da) allows good skin penetration. A 2022 pilot study (PMID 35163025) confirmed topical CTP improves skin parameters. The two routes likely complement each other and can be used together.

At what concentration should Tripeptide-29 be used topically?

Commercial formulation guidelines recommend incorporating Tripeptide-29 at 0.1-1% by volume in finished cosmetic products. Raw ingredient solutions are typically sold at 0.5% concentration in a water/glycerin vehicle and are meant to be incorporated into final formulations at the recommended usage rate. Tripeptide-29 is 100% water-soluble and should be added during the water phase of emulsion preparation. Optimal formulation pH is 4.0-7.0. Higher concentrations have not been shown to cause adverse effects but may not provide proportionally greater benefit.

How long does it take to see results?

Clinical studies show measurable improvements beginning at 4 weeks for both topical and oral use. The 2022 topical pilot study (PMID 35163025) demonstrated significant wrinkle, elasticity, and density improvements at 4 weeks. Oral CTP RCTs show statistically significant hydration and elasticity improvements at 4-8 weeks (PMID 24131075), with continued improvement through 12 weeks (PMID 33521019). For optimal and sustained results, consistent daily use for at least 8-12 weeks is recommended.

Should people on blood thinners be cautious with Tripeptide-29?

The cited platelet study (Knight et al. 1999, PMID 10341844) tested longer peptides containing repeated Gly-Pro-Hyp sequences, which activated platelet glycoprotein VI (GPVI), the receptor that mediates collagen-induced platelet activation. It did not measure systemic exposure after topical Tripeptide-29 or interactions between oral Tripeptide-29 and blood thinners. Other collagen-derived peptides have been shown to inhibit platelet aggregation (PMID 34360155). As a precaution, people on anticoagulant or antiplatelet medications should consult their physician before taking high-dose oral CTP supplements.